Infectious Disease, Immunology & Vaccines

Lead text placeholder. Lorem ipsum dolor sit amet, consectetur adipisicing elit.

Articles

2018. Pialoux G et al. – Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France
2017. Prabhu VS et al. – Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States
2017. Prabhu V et al. – Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK
2017. Mennini FS et al. – Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
2017. Kauf TL et al. – Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections
2017. Brengard-Bresler T et al. – Postoperative quality of life of patients with a bacterial necrotizing dermis-hypodermitis or necrotizing fasciitis, a ten-year study
2017. Largeron N et al. – An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany
2017. Stahmeyer JT et al. – Cost-effectiveness of treating hepatitis C with lofosbuvir/ledipasvir in Germany
2017. Igarashi A et al. – Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan
2017. Igarashi A et al. – Cost-utility analysis of ledipasvir/ sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan
2016. Martinez F et al. – Scoring and psychometric validation of the ‘Determinants of Intentions to Vaccinate’ (DIVA©) questionnaire
2016. Lopez-Belmonte JL et al. – The use of Zostavax in Spain: The economic case for vaccination of individuals aged 50 years and older
2016. Martinez L et al. – The commitment of French general practitioners to vaccination: The DIVA study (Determinants of Vaccination Intentions)
2015. Pialoux G et al. – Cost-effectiveness of dolutegravir in HIV-1 treatment-experienced (TE) patients in France
2015. Cure S et al. – Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients
2015. De Coster I et al. – Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines
2015. Cure S et al. – Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy
2015. Nilsson J et al. – Burden of herpes zoster and post-herpetic neuralgia in Sweden
2015. Guillemin I et al. – How do Clostridium difficile infections affect nurses’ everyday hospital work: A qualitative study
2014. Sterling K et al. – Patient-reported fatigue and its impact on patients with systemic lupus erythematosus
2014. Guillemin I et al. – Patients’ experience and perception of hospital-treated Clostridium difficile infections: A qualitative study
2013. Dominiak-Felden G et al. – Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: Results of an observational, health-related quality of life study in the UK
2012. Littlewood KJ et al. – A network meta-analysis of the efficacy of inhaled antibiotics for chronic pseudomonas infections in cystic fibrosis
2012. Gallop K et al. – Development of a conceptual model of health-related quality of life for systemic lupus erythematosus from the patient’s perspective
2012. Diez-Domingo J et al. – The impact of childhood acute rotavirus gastroenteritis on the parents’ quality of life: Prospective observational study in European primary care medical practices
2012. Ghosh S et al. – Epidemiology of HIV-related neuropathy: A systematic literature review
2011. Vieira MC et al. – Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: A mixed treatment comparison
2010. Viala-Danten M et al. – Psychometric evaluation of the Functional Assessment of HIV Infection (FAHI) questionnaire and its usefulness in clinical trials
2010. de Peuter MA et al. – Cost-effectiveness of catch-up programs in human papillomavirus vaccination
2010. Reygrobellet C et al. – Perception and acceptance of intradermal influenza vaccination: Patient reported outcomes from phase 3 clinical trials
2010. Arnould B et al. – The impact of herpes zoster and subsequent chronic pain on patients’ daily lives
2010. Cella D et al. – Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the functional assessment of human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials
2009. Regnault A et al. – Satisfactory cross-cultural validity of the ACTG symptom distress module in HIV-1-infected antiretroviral-naive patients
2009. Higgins N et al. – Antiretroviral therapeutic drug monitoring in Canada: Current status and recommendations for clinical practice
2009. Spire B et al. – Simplification and first validation of a short battery of patient questionnaires for clinical management of HIV-infected patients: The HIV-SQUAD (Symptom QUality of life ADherence) questionnaire®
2009. Jansen JP et al. – Cost-effectiveness evaluation of ertapenem versus piperacillin/ tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance
2009. Chevat C et al. – Development and psychometric validation of a self-administered questionnaire assessing the acceptance of influenza vaccination: the Vaccinees’ Perception of Injection (VAPI©) questionnaire
2009. Jansen JP et al. – Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK
2008. Hillemanns et al. – Estimation of the incidence of genital warts and the cost of illness in Germany: A cross-sectional study

Posters & Presentations

2017. ISPOR European Congress – Network meta-analysis in the evaluation of vaccines
2017. ISPOR European Congress – Processes and requirements for health economic assessment of antibiotics for HTA purposes: Time for a paradigm shift?
2017. ISPOR European Congress – Systematic literature review of economic evaluations and healthcare resource utilisation studies in the treatment of clostridium difficile infection
2017. ISPOR European Congress – Systematic literature review of health-related quality of life in clostridium difficile infection
2017. ISPOR European Congress – Vaccines for Herpes Zoster: A systematic review of randomized controlled trials in adults ≥50 years of age
2017. CDISC Europe Interchange – Lessons learned when developing over time an integrated database compliant with SDTM for vaccines clinical trials
2016. ISPOR European Congress – Estimating the Management Cost of HPV-Related Low-Grade and PreCancerous High-Grade Lesions in France
2016. BASHH Annual Conference – A Qualitative Evaluation of the Patients Know Best® (PKB) Patient-Controlled Electronic Medical Record and Communication Platform in UK HIV Services
2015. ISPOR European Congress – Are Antimicrobials Paving the Way for All Pharmaceuticals?
2015. ISPOR European Congress – Using an Economic Model to Choose Initial Appropriate Antibiotic Therapy Based on Differences in In-Vitro Susceptibility to Ceftolozane/ Tazobactam and Piperacillin/Tazobactam
2015. ISPOR European Congress – Are Vaccines Getting a Fair Deal? Health Technology Assessment of Vaccines Across Europe
2015. ISPOR European Congress – Cost-Effectiveness of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir for Patients with Chronic HCV in the Netherlands
2015. ISPOR European Congress – Cost per Patient with Sustained Viral Response for Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavarin in Genotype 1 Patients With Chronic HCV in the Netherlands
2015. ISPOR European Congress – Scoring and Measurement Properties of a Tool to Assess Primary Care Physicians’ Engagement in and Perceived Barriers to Vaccination: “The Determinant of Intentions of Vaccination (DIVA) Questionnaire”
2015. ISPOR European Congress – Reduction in Costs over Two Years when Treating with Darunavir/Ritonavir Compared to Atazanavir/Ritonavir in the UK
2015. ISPOR European Congress – Estimating the Public Health Impact of a Vaccination Programme with a Nonavalent HPV Vaccine in Germany
2015. ISPOR European Congress – Estimating the Cost-Effectiveness Profile of a Vaccination Programme with a Nine-Valent HPV Vaccine in Italy
2014. ISPOR European Congress – Relationship Between Microbiological Eradication and Clinical Outcome with Antibiotic Treatment in Nosocomial Pneumonia, Complicated Urinary Tract Infection, and Complicated Intra-Abdominal Infection
2014. ISPOR European Congress – Literature Review of Decision-Analytical Models Used in the Economic Evaluation of Empirical/Targeted Antifungal Treatments for Invasive Fungal Infections
2014. ISPOR European Congress – Systematic Literature Review Assessing Data on the Burden of Allergic Rhinitis from a Cost and Quality of Life Perspective
2014. ICPE Meeting – Real World Utilization and Management of Adverse Events in Patients Treated with Direct Acting Antivirals (DAAs) in a European Cohort of Chronic Hepatitis C (CHC) Patients
2014. ISPOR Annual International Meeting – Sustained Improvements in Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus Following Epratuzumab Treatment: Results from a Phase IIB Study and its Open-Label Extension
2013. ISPOR European Congress – What Value Can Operational Feasability Studies Bring to Post Marketing Observational Studies (PMOS)? Example of Feasability Study in Eastern Europe to Assess Hepatitis C Viral Disease/Patient Management in Real World Setting
2013. ISPOR European Congress – Attitudes, Beliefs and Behaviours of General Practitioners Regarding Vaccinations: Development of a Characterisation Tool – Qualitative Steps
2012. ISPOR European Congress – Efficacy of Ceftaroline Fosamil and Other Intravenous Antibiotics in the Treatment of Community-Acquired Pneumonia (CAP): A Network Meta-Analysis (NMA)
2012. ISPOR European Congress – Efficacy of Ceftaroline Fosamil and Other Intravenous Antibiotics in the Treatment of Complicated Skin and Soft Tissue Infections (CSSTI): A Network Meta-Analysis (NMA)
2012. ISPOR European Congress – Pharmacoeconomic Evaluation of the Introduction of Universal Varicella Vaccination in Italy
2011. ISPOR European Congress – Burden of Herpes Zoster and Post-Herpetic Neuralgia: Findings from a Cross-Sectional Patient Reported Outcomes Study
2011. ISPOR European Congress – Development of A Large Safety Database Using Studies Conducted During the Clinical Development and Post-Marketing of A Virosomal Aluminium-Free Hepatitis A Vaccine
2011. ISPOR European Congress – Epidemiology of Staphylococcus Aureus Infections in Children: A Literature Review of the Last 10 Years
2011. ISPOR Latin America Conference – Replacing MMR by MMRV in Mexico: Assessment of Cost-Effectiveness Based on a Dynamic Transmission Model
2011. ISPOR Annual International Meeting – Epidemiology of HIV-Related Neuropathy – A Systematic Literature Review
2010. ISPOR European Congress – Impact of Herpes Zoster and Postherpectic Neuralgia on Patients’ Quality of Life
2010. ISPOR European Congress – Herpes Zoster and Post-Herpetic Neuralgia: Considerations for a Prospective, Cross-Sectional Patient-Reported Outcomes Study
2010. ISPOR European Congress – Impact of MMRV Mass Vaccination with or without a Catch-Up Program on the Incidence of Varicella Complications in France
2009. ISPOR European Congress- Perception and Acceptance of Intradermal Influenza Vaccine Measured by the Vaccinee’s Perception on Injection (VAPI©) Questionnaire
2009. ISPOR European Congress -Translation of the HIV Patient Symptoms Profile into 5 Languages Spoken in Israel
2009. ISPOR European Congress – Perception and Acceptance of Intradermal Influenza Vaccine Measured by the Vaccinee’s Perception on Injection (VAPI©) Questionnaire
2009. ISPOR European Congress – Psychometric Evaluation of the Functional Assessment of HIV Infection (FAHI) Questionnaire in Two Clinical Programmes
2009. ISPOR European Congress – Cost-Effectiveness of Mass Varicella Vaccination in France: Economic Consequences of an Intensive Vaccination Program
2009. ISPOR European Congress – How Do Patients Describe Their Symptoms of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)? Qualitative Interviews with Patients to Support the Development of a Patient-Reported Symptom-Based Screener for IC/PBS
2008. ISPOR European Congress – Modeling of Infectious Diseases and their Treatment for Health Economic Analysis
2008. ISPOR European Congress – Cost-Effectiveness of Mass Vaccination for Varicella in France with MMRV Versus MMR
2008. ISPOR European Congress – Impact of Mass Vaccination with MMRV versus MMR in France on the Epidemiology of Varicella and Herpes Zoster Using a Dynamic Transmission Model
2008. ISPOR Annual International Meeting – Assessment of the Cross-Cultural Valididty of an HIV Symptom Distress Module in an International HIV Clinical Trial
2005. ISPOR European Congress – Podium: Cost-Effectiveness of Voriconazole versus Liposomal Amphotericin B for Invasive Aspergillosis Infection in the UK
2005. ISPOR European Congress – Resource Use and Costs Associated with the Management of PAP III, PAP IIID AND PAP IV in the Pre-HPV Vaccine Era in Germany
2005. ISPOR European Congress – Development, Pilot Testing, Scoring and Validation of a Management Tool for Patients Undergoing Specific Immuno-Therapy